Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Technical Presentation (October 2026)
19 slides from Century Therapeutics's technical presentation, Oct 2, 2026
Slide 1: Scalable Production of Allo-Evasion 5.0-Engineered iPSC Islets for Off-the-Shelf Cell Therapies
CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research
Slide 2: Disclosures
2 Disclosures Presenter G. Grant Welstead, PhD Relevant Financial Relationship • Employee, Century Therapeutics Presentation Information • This presentation describes preclinical research related to CNTY - 813, an investigational iPSC - derived islet cell therapy for T1D • The content is intended fo
Slide 3: Forward-looking statements
3 This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relat
Slide 4: Islet transplantation provides a potentially curative therapy for T1D
4 Islet transplantation provides a potentially curative therapy for T1D Supply and chronic immunosuppression limit the broader use of T1D cell therapies Islet cell transplantation provides potential for curative therapy in T1D In T1D, islet cells are destroyed Healthy islet cells produce insulin (gr
Slide 5: Scalable manufacturing, islet function, and immune-evasive engineering address key barriers
5 • Scalable iPSC - derived islet manufacturing • Reproducible islet differentiation • Clinical manufacturing process from GMP MCB Differentiation platform Functional islets ALLO - EVASION 5.0 Scalable manufacturing, islet function, and immune - evasive engineering address key barriers for T1D cell
Slide 6: Generation of islets with a 29-day defined process
6 6 Stage 1 Stage 2 Stage 4 Stage 5 Stage 6 Stage 3 Generation of islets with a 29 - day defined process High purity and reproducible across batches iPSC Definitive Endoderm Primitive Gut Tube Pancreatic Progenitor II Endocrine β Cell Pancreatic Progenitor I Stage 1 Definitive Endoderm Stage 4 Pancr
Slide 7: Islets contain defined, terminally differentiated endocrine cell populations
7 CNTY - 813 islets contain defined, terminally differentiated endocrine cell populations Population Enriched Markers: β - cell: INS, NKX6.1; ⍺ - cell: GCG,ARX; δ - cell: SST; Exocrine/Ductal: KRT19; FEV+ Islet Cell: FEV+SLC18A1+ Diff. Stage: scRNAseq Cell Cycle Annotations scRNAseq Cell Type Annota
Slide 8: Islet cells demonstrate robust glucose-responsive function
8 CNTY - 813 islet cells demonstrate robust glucose - responsive function Nonclinical Potency Stimulation Index Total Insulin Content Glucose Stimulated Insulin Secretion iPSC- Islets Primary Islets 0 10000 20000 30000 40000 u I U I n s u l i n / 1 E 6 C e l l s 2mM Glucose 20mM Glucose ∆ GSIS i P S
Slide 9: Islets provided durable glycemic control for >11 months
9 CNTY - 813 provided durable glycemic control for >11 months, with reversal after graft removal demonstrating clear pharmacological activity CNTY - 813 islets rapidly restored normoglycemia in STZ - induced diabetic mice Nonclinical Potency 0 20 40 60 80 100 120 0 100 200 300 400 500 600 Time (min)
Slide 10: Grafts maintain endocrine identity with no evidence of tumorigenesis in mouse models
10 CNTY - 813 grafts maintain endocrine identity with no evidence of tumorigenesis in mouse models Endocrine graft identity over time INS+ (green) CHGA+ (orange) Merged (yellow) Ki67+ (pink) DAPI (blue) INS: Insulin stain; CHGA: CHGA stain; Ki67: Stain for human and mouse Ki67; DAPI: nuclear stain 4
Slide 11: Engineered to evade T cell, NK cell, and humoral responses
11 CNTY - 813 is engineered to evade T cell, NK cell, and humoral responses b2M KO (HLA - I) CIITA KO (HLA - II) CD8 + T Cell CD4 + T Cell Pan NK Inhibitory ligand Fc NK cell No HLA - I Prevents recognition by CD8+ cells T cells No HLA - II Prevents recognition by CD4+ cells T cells IgG Cleavage Red
Slide 12: Demonstrated protection from multiple immune effector mechanisms
12 CNTY - 813 demonstrated protection from multiple immune effector mechanisms Reduced NK Cell Activation NK - CELL Protection IgG Cleavage Protected from phagocytosis Rapid IgG Cleavage Reduced Antibody - Dependent Phagocytosis (ADCP) 01 02 03 Reduced NK Cell Cytotoxicity 0.25:1 0.5:1 1:1 2:1 10 20
Slide 13: Humanized mouse engrafted with healthy donor PBMCs
13 Humanized Mouse Engrafted with Healthy Donor PBMCs Employing a humanized mouse model to study allogeneic graft rejection • Functional human T cells without GvHD (MHC DKO) – Supports longer study durations • Supports engraftment and survival of human NK cells (TgHu - IL15) • Testing of allo - reje
Slide 14: Allo-Evasion 5.0 protected from rejection in a humanized mouse model
14 Allo - Evasion 5.0 maintained CNTY - 813 Glucose Stimulated Insulin Secretion and GTT performance in vivo1 Allo - EvasionTM 5.0 protected CNTY - 813 from rejection in a humanized mouse model Glucose Stimulation Index Glucose Tolerance Test (GTT) (11 weeks post - islet infusion) Reduced function w
Slide 15: Phase 1 clinical manufacturing process established from MCB
15 Phase 1 clinical manufacturing process established and executed from MCB across multiple independent batches MCB Thaw iPSC Expansion Bioreactor Differentiation Cryopreserved Intermediate Post - Thaw Maturation Final Fresh Product Consistent final product flow cytometry profiles across 5 clinical
Slide 16: Successful engraftment in rat livers via portal vein injection
16 Successful CNTY - 813 engraftment in rat livers via portal vein injection Vehicle Control CNTY - 813 – H&E CNTY - 813 – IF PV HA BD HA HA BD BD CNTY - 813 BD HA BD CNTY - 813 BD HA BD DAPI Chromogranin A Insulin CNTY - 813 CNTY - 813 aggregates are identified in the liver at 1 - month post - tran
Slide 17: Clinical-scale islets restored durable normoglycemia after 96 hours in cold storage
17 IPGTT= Intraperitoneal Glucose Tolerance Test Source: Company data on file Clinical - scale islets restored durable normoglycemia after 96 - hours in cold storage Clinical - scale product with 96 - hour cold storage stability Islets manufactured at clinical scale retained full functionality after
Slide 18: Demonstrated reproducible differentiation, durable glucose control, and immune-evasive function
18 CNTY - 813 demonstrated reproducible differentiation, durable glucose control, and immune - evasive function in preclinical models • Reproducible, bioreactor - enabled differentiation from GMP MCB • Phase 1 clinical manufacturing process established • CNTY - 813 specs: – >95% islet endocrine – >5
Slide 19: Acknowledgements
19 Acknowledgements Mike Brehm & Lab – UMASS Chan School of Medicine and Diabetes Center of Excellence 19 Entire Century Team
Century Therapeutics — Technical Presentation (October 2026) on 6ix